RWC Update: GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Concern or Coincidence?; The Glowport; Retinocytoma

Ophthalmic surgery, lasers & imaging retina 2026 Open access

Read full text
Authors: Ashish Sharma, Lihteh Wu, Steven Bloom, Paulo Eduardo Stanga, Cindy X. Cai, Rishi P. Singh, Shishir Verghese, Prithvi Chandrakanth, Dibya Prabha, Kourous A. Rezaei
DOI: 10.3928/23258160-20260114-01
Cited by: 0
References: 13

Abstract

The potential link between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION) has generated increasing debate, with limited and conflicting evidence to date.As use of these agents continues to expand, understanding of any true ocular risk is essential.In this column, expert perspectives help clarify the data, explore biological plausibility, and separate concern from coincidence.Cindy X. Cai, MD, MS.Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity because they effectively lower glucose and promote weight loss.Beyond these

Fields of Study & Subjects

Drug-Induced Ocular Toxicity Retinal Diseases and Treatments Diabetes Treatment and Management

Publication details

Journal / source
Ophthalmic surgery, lasers & imaging retina
Volume
57
Issue
2
Pages
73–76
Publication date
1 February 2026
Language
EN